JP2020022459A5 - - Google Patents

Download PDF

Info

Publication number
JP2020022459A5
JP2020022459A5 JP2019169775A JP2019169775A JP2020022459A5 JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5 JP 2019169775 A JP2019169775 A JP 2019169775A JP 2019169775 A JP2019169775 A JP 2019169775A JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5
Authority
JP
Japan
Prior art keywords
seq
adenovirus
vector
transgene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019169775A
Other languages
English (en)
Japanese (ja)
Other versions
JP7394285B2 (ja
JP2020022459A (ja
Filing date
Publication date
Priority claimed from JP2018137237A external-priority patent/JP6970647B2/ja
Application filed filed Critical
Publication of JP2020022459A publication Critical patent/JP2020022459A/ja
Publication of JP2020022459A5 publication Critical patent/JP2020022459A5/ja
Application granted granted Critical
Publication of JP7394285B2 publication Critical patent/JP7394285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019169775A 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法 Active JP7394285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543661P 2011-10-05 2011-10-05
US61/543,661 2011-10-05
JP2018137237A JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018137237A Division JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Publications (3)

Publication Number Publication Date
JP2020022459A JP2020022459A (ja) 2020-02-13
JP2020022459A5 true JP2020022459A5 (enExample) 2020-03-26
JP7394285B2 JP7394285B2 (ja) 2023-12-08

Family

ID=47045181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2019169775A Active JP7394285B2 (ja) 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Country Status (7)

Country Link
US (4) US9617560B2 (enExample)
EP (1) EP2764014B1 (enExample)
JP (3) JP6757121B2 (enExample)
CN (2) CN107574154A (enExample)
BR (1) BR112014008284A2 (enExample)
CA (1) CA2851251C (enExample)
WO (1) WO2013052832A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764013B1 (en) 2011-10-05 2022-01-26 GenVec, Inc. Adenoviral vectors and methods of use
JP6757121B2 (ja) * 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
ES2959811T3 (es) 2016-12-09 2024-02-28 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
WO2019086466A1 (en) * 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FI951138A7 (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2000504223A (ja) 1996-01-29 2000-04-11 ジョージタウン・ユニヴァーシティ Msa1ペブチドの付加に基づいたマラリアワクチン
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
JP2005503797A (ja) 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
US7851218B2 (en) 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
US7628993B2 (en) 2006-07-20 2009-12-08 Vical Incorporated Compositions and methods for vaccinating against HSV-2
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
MX2012001404A (es) 2009-07-31 2012-06-01 Paxvax Inc Vectores de base adenoviral.
CA2779632C (en) * 2009-11-09 2019-08-20 Jason Gall Simian adenovirus and methods of use
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP2764013B1 (en) 2011-10-05 2022-01-26 GenVec, Inc. Adenoviral vectors and methods of use
JP6757121B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
WO2013116591A1 (en) * 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine

Similar Documents

Publication Publication Date Title
JP2020022459A5 (enExample)
JP2023082054A5 (enExample)
JP2010227108A5 (enExample)
JP2021112211A5 (enExample)
JP2019214579A5 (enExample)
JP2010065037A5 (enExample)
JP2020505025A5 (enExample)
JP2016537341A5 (enExample)
JP2019522461A5 (enExample)
JP2012505657A5 (enExample)
JP2019528793A5 (enExample)
JP2016146837A5 (enExample)
JP2016501531A5 (enExample)
JP2011087580A5 (enExample)
JP2003514526A5 (enExample)
JP2013539454A5 (enExample)
JP2017534262A5 (enExample)
JP2017532302A5 (enExample)
JP2010532978A5 (enExample)
JP2008525033A5 (enExample)
JP2010534684A5 (enExample)
JP2011155981A5 (enExample)
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru) Композиция вакцины
WO2017194903A3 (fr) Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune